1. Definition

Chronic hepatitis B virus (HBV) infection is persistent HBV infection characterized classically by HBsAg positivity for ≥6 months, with or without detectable HBV DNA, HBeAg, or clinical liver disease.

Chronic HBV infection is not synonymous with chronic hepatitis.

A person may have:

• Persistent HBsAg with minimal liver inflammation

• High HBV DNA with normal ALT

• Low HBV DNA with normal ALT

• Active chronic hepatitis with fluctuating ALT and HBV DNA

• Advanced fibrosis or cirrhosis

• Hepatocellular carcinoma (HCC)

Therefore, chronic HBV infection is a dynamic disease with changing levels of viral replication, host immune activity and liver injury.

2. How Acute HBV Becomes Chronic

The probability of chronicity is strongly dependent on the age at infection.

The major determinant is the ability of the host immune system to mount an effective HBV-specific response.

Why is neonatal infection so likely to become chronic?

Neonates and young infants have an immature/ineffective HBV-specific immune response. High levels of circulating HBeAg and viral antigen exposure may also contribute to immune tolerance/dysfunction.

3. Fundamental Virological Basis of Chronicity

The ability of HBV to persist is related to its unusual replication strategy.

After entry into hepatocytes:

HBV DNA → nucleus → relaxed circular DNA (rcDNA) → cccDNA

The viral covalently closed circular DNA (cccDNA) forms a stable episomal minichromosome in the hepatocyte nucleus.

It serves as the major intracellular template for:

• HBV RNA transcription

• pgRNA production

• viral protein production

• continuing viral replication

Therefore:

cccDNA persistence → viral persistence → possibility of lifelong infection

Even after suppression of serum HBV DNA, intrahepatic cccDNA may remain.

4. Chronic HBV Is Primarily an Immune-Mediated Disease

HBV itself is not strongly cytolytic.

Much of the liver damage results from the host immune response against HBV-infected hepatocytes.

Simplified mechanism

HBV infection

↓

Viral antigen expression in hepatocytes

↓

HBV-specific CD8⁺ T-cell and CD4⁺ T-cell responses

↓

Cytotoxicity + inflammatory cytokines

↓

Hepatocyte injury

↓

Repeated necroinflammation

↓

Fibrogenesis

↓

Cirrhosis ± HCC

Thus:

5. Immunopathogenesis of Chronic HBV

5.1 Effective immune response

A strong, multispecific HBV-specific T-cell response can produce:

• reduction of HBV replication

• HBeAg seroconversion

• suppression of HBV DNA

• eventual HBsAg loss in a minority of patients

5.2 Ineffective immune response

Chronic infection is associated with:

• weak HBV-specific T-cell responses

• impaired T-cell functionality

• T-cell exhaustion

• persistent antigen exposure

• regulatory immune mechanisms

• altered innate immune responses

HBV-specific T cells may express inhibitory receptors such as:

• PD-1

• CTLA-4

• TIM-3

• other exhaustion-associated pathways

These mechanisms contribute to ineffective viral clearance.

6. Role of HBeAg

HBeAg is not simply a marker of viral replication.

It may influence host immunity and contribute to establishment of persistent infection, particularly when infection occurs early in life.

Historically, chronic HBV was divided into:

• immune-tolerant phase

• immune-active phase

• inactive carrier phase

• reactivation phase

These terms remain clinically useful, but modern guidelines emphasize that HBV infection is dynamic rather than four rigid boxes.

7. Modern Phases of Chronic HBV Infection

A practical framework recognizes:

1. HBeAg-positive chronic infection

2. HBeAg-positive chronic hepatitis

3. HBeAg-negative chronic infection

4. HBeAg-negative chronic hepatitis

5. Indeterminate/grey-zone states

Older terminology is still encountered:

8. Phase 1 — HBeAg-Positive Chronic Infection

Typical characteristics

• HBsAg positive

• HBeAg positive

• HBV DNA very high

• ALT normal or minimally elevated

• Liver inflammation usually limited

• Fibrosis often minimal, particularly in younger patients

Historically called the immune-tolerant phase.

However, the term "immune tolerant" can be misleading, particularly in adults.

Typical profile

Clinical significance

High HBV DNA does not automatically mean severe liver disease.

A patient may have:

Very high HBV DNA + normal ALT + minimal fibrosis

Therefore, viral load alone should not be interpreted as equivalent to current hepatic injury.

9. Phase 2 — HBeAg-Positive Chronic Hepatitis

This represents an active immune response against HBV-infected hepatocytes.

Typical characteristics

• HBeAg positive

• HBV DNA high

• ALT elevated

• Active hepatic inflammation

• Progressive fibrosis may develop

Pathogenesis

HBV replication

↓

Increasing antigen expression

↓

HBV-specific immune response

↓

Hepatocyte injury

↓

ALT elevation

↓

Necroinflammation

↓

Fibrosis

↓

Possible cirrhosis

10. HBeAg Seroconversion

One of the major transitions in chronic HBV infection is:

HBeAg loss + appearance of anti-HBe

This is called:

HBeAg seroconversion

It usually reflects improved immune control over viral replication.

It is often associated with:

• marked fall in HBV DNA

• normalization of ALT

• transition to HBeAg-negative chronic infection

However:

HBV DNA may remain detectable and HBsAg usually persists.

11. Phase 3 — HBeAg-Negative Chronic Infection

This state is often called the inactive carrier state in older literature.

Modern terminology:

HBeAg-negative chronic infection

Typical features:

• HBsAg positive

• HBeAg negative

• anti-HBe usually positive

• HBV DNA usually <2,000 IU/mL

• ALT persistently normal

• minimal necroinflammation

• low fibrosis risk compared with active disease

Typical profile

12. Why "Inactive Carrier" Can Be Misleading

A patient who appears inactive at one point may later develop:

HBV reactivation → increased HBV DNA → ALT elevation → chronic hepatitis

Therefore, a single normal ALT and low HBV DNA does not permanently classify the patient as inactive.

Long-term monitoring is essential.

13. Phase 4 — HBeAg-Negative Chronic Hepatitis

This is an important and clinically significant form of chronic HBV.

Patients are:

• HBeAg negative

• usually anti-HBe positive

• HBV DNA elevated

• ALT elevated or fluctuating

• at risk of progressive fibrosis and cirrhosis

The disease may alternate between:

low replication → viral flare → partial suppression → relapse

14. Why Is HBeAg Negative but HBV Replication Continues?

The most important explanation is the emergence of HBV variants affecting HBeAg production.

Important variants

Precore mutations

Particularly:

G1896A

This creates a stop codon in the precore region and prevents effective HBeAg production.

Therefore:

HBeAg negative ≠ HBV replication absent

Basal core promoter mutations

Changes in the basal core promoter can reduce HBeAg production while allowing continued viral replication.

Therefore:

HBeAg-negative chronic hepatitis = active HBV disease despite absence of HBeAg

15. Comparison of the Major Chronic HBV States

16. The "Grey Zone" / Indeterminate Phase

Many patients do not fit neatly into the traditional four phases.

Examples:

• HBV DNA ≥2,000 IU/mL but normal ALT

• HBV DNA <2,000 IU/mL but elevated ALT

• fluctuating ALT

• fluctuating HBV DNA

• intermediate HBV DNA levels

• older patient with apparently normal ALT but significant fibrosis

These patients are often described as being in an:

Indeterminate or grey-zone phase

This is clinically important because treatment decisions may depend on:

• age

• fibrosis

• family history of HCC

• HBV DNA

• ALT

• platelet count

• liver stiffness

• comorbid liver disease

• previous treatment

• duration of infection

Modern guidelines increasingly recognize the importance of this group.

17. Chronic HBV Is a Dynamic Process

A simplified natural history:

Acquisition of HBV

↓

Chronic infection

↓

HBeAg-positive chronic infection

↓

HBeAg-positive chronic hepatitis

↓

HBeAg seroconversion

↓

HBeAg-negative chronic infection

↓

Either:

Long-term low-level infection

OR

HBeAg-negative chronic hepatitis/reactivation

↓

Progressive fibrosis

↓

Cirrhosis

↓

Decompensation ± HCC

However, patients can move back and forth between states.

18. Major Outcomes of Chronic HBV

Chronic HBV may result in:

1. Long-term inactive infection

Minimal liver injury.

2. HBeAg seroconversion

Often associated with reduced viral replication.

3. HBsAg loss

The desired long-term virological endpoint.

4. Chronic hepatitis

Persistent or fluctuating inflammation.

5. Fibrosis

Progressive deposition of extracellular matrix.

6. Cirrhosis

Advanced architectural distortion.

7. Hepatic decompensation

Including:

• ascites

• variceal bleeding

• hepatic encephalopathy

• jaundice

• coagulopathy

8. Hepatocellular carcinoma

May occur with or without cirrhosis.

19. HBsAg Loss — Functional Cure

The ideal endpoint of chronic HBV treatment is:

HBsAg loss ± anti-HBs development

This is often termed:

Functional cure

rather than complete eradication.

Why?

Because:

• cccDNA may persist

• integrated HBV DNA may remain

• HBV reactivation can rarely occur under profound immunosuppression

Therefore:

20. Fibrosis and Cirrhosis

Persistent hepatic inflammation activates:

• Kupffer cells

• hepatic stellate cells

• inflammatory pathways

Important profibrotic mediators include:

• TGF-β

• PDGF

• inflammatory cytokines

Activated stellate cells transform into myofibroblast-like cells.

↓

Extracellular matrix production

↓

Collagen deposition

↓

Bridging fibrosis

↓

Cirrhosis

21. Why Cirrhosis Develops

Risk is increased by:

• persistent high HBV DNA

• persistent ALT elevation

• active chronic hepatitis

• prolonged duration of infection

• older age

• male sex

• alcohol

• metabolic dysfunction-associated steatotic liver disease

• HDV coinfection

• HCV coinfection

• HIV coinfection

• immunosuppression/reactivation

• viral variants

• family history of HCC

22. Hepatocellular Carcinoma in Chronic HBV

HBV is particularly important because:

Mechanisms include:

1. Chronic inflammation

Repeated hepatocyte injury and regeneration promote carcinogenesis.

2. HBV DNA integration

HBV DNA may integrate into the host genome.

This can cause:

• genomic instability

• altered gene expression

• chromosomal abnormalities

3. HBx protein

HBx has been implicated in:

• transcriptional regulation

• signaling pathways

• apoptosis

• DNA damage responses

• epigenetic regulation

4. Pre-S mutations

Certain pre-S region mutations are associated with hepatocyte stress and carcinogenesis.

5. Persistent regeneration

Repeated cycles of:

injury → regeneration → mutation

increase malignant transformation risk.

23. HBV DNA and HCC Risk

Long-term HBV replication is an important determinant of disease progression.

In general:

Higher persistent HBV DNA → greater risk of cirrhosis/HCC

But risk is not determined by viral load alone.

Other determinants include:

• age

• sex

• fibrosis

• ALT

• family history

• HBV genotype/variants

• alcohol

• metabolic factors

• HDV/HCV/HIV coinfection

24. Clinical Manifestations of Chronic HBV

Many patients are completely asymptomatic.

Early chronic infection

Often:

• asymptomatic

• normal physical examination

• incidental HBsAg detection

Possible nonspecific symptoms:

• fatigue

• malaise

• anorexia

• mild right upper quadrant discomfort

25. Chronic Hepatitis Flares

Chronic HBV can undergo episodic exacerbations.

Typical pattern:

Increase in HBV DNA

↓

ALT flare

↓

Possible:

• malaise

• nausea

• jaundice

• abdominal discomfort

Severe flares can lead to:

• acute-on-chronic liver failure

• hepatic decompensation

26. Chronic HBV and Cirrhosis

Once advanced cirrhosis develops, manifestations may include:

Portal hypertension

• splenomegaly

• thrombocytopenia

• esophageal/gastric varices

• ascites

Hepatic dysfunction

• jaundice

• hypoalbuminemia

• prolonged INR

• encephalopathy

Complications

• variceal hemorrhage

• spontaneous bacterial peritonitis

• hepatorenal syndrome

• hepatopulmonary syndrome

• HCC

27. Extrahepatic Manifestations

Chronic HBV is associated with several immune-complex mediated diseases.

Important examples:

Polyarteritis nodosa

Classically associated with HBV.

Features may include:

• fever

• myalgia

• hypertension

• abdominal pain

• neuropathy

• skin manifestations

• renal involvement

Glomerular disease

Reported associations include:

• membranous nephropathy

• membranoproliferative glomerulonephritis

Possible findings:

• proteinuria

• hematuria

• edema

• nephrotic/nephritic syndromes

Other manifestations

• arthralgia

• serum-sickness-like syndrome

• mixed cryoglobulinemia

28. Factors Associated With Disease Progression

29. HBV and HDV Coinfection

HDV is particularly important because it can accelerate:

• necroinflammation

• fibrosis

• cirrhosis

• hepatic decompensation

• HCC risk

Every patient with chronic HBV should be assessed according to contemporary recommendations for HDV testing, particularly where indicated by epidemiology or clinical risk.

30. Chronic HBV During Immunosuppression

A patient with chronic or previous HBV infection can experience:

HBV reactivation

This occurs when immune control is weakened.

Common settings:

• chemotherapy

• hematological malignancies

• anti-CD20 therapy such as rituximab

• stem-cell transplantation

• organ transplantation

• prolonged immunosuppressive therapy

• certain biologic therapies

Reactivation may cause:

HBV DNA rise → ALT flare → hepatitis → hepatic failure

Importantly, even some HBsAg-negative/anti-HBc-positive individuals can reactivate.

31. Laboratory Profile of Chronic HBV

Essential investigations include:

Virological

• HBsAg

• HBeAg

• anti-HBe

• total anti-HBc

• IgM anti-HBc when acute flare is suspected

• HBV DNA

Liver injury

• ALT

• AST

• bilirubin

• alkaline phosphatase

Liver function

• albumin

• PT/INR

Disease severity

• platelet count

• ultrasound

• transient elastography

• appropriate non-invasive fibrosis scores

• biopsy in selected cases

32. Typical Serological Profile

HBeAg-positive chronic infection

HBsAg +HBeAg +anti-HBc total +anti-HBe −HBV DNA very high

HBeAg-negative chronic infection

HBsAg +HBeAg −anti-HBe +anti-HBc total +HBV DNA usually low

HBeAg-negative chronic hepatitis

HBsAg +HBeAg −anti-HBe usually +HBV DNA elevated/fluctuatingALT elevated/fluctuating

33. Important Distinction: Chronic Infection vs Chronic Hepatitis

Chronic HBV infection

Means persistent HBV infection.

Chronic hepatitis B

Means chronic HBV infection with clinically relevant hepatic inflammation/activity.

Therefore:

34. Occult HBV Infection

Occult HBV infection is distinct from conventional HBsAg-positive chronic HBV.

Definition broadly involves:

HBV DNA persistence in liver ± low-level HBV DNA in blood despite absence of detectable HBsAg.

Anti-HBc may be positive.

This becomes particularly important in:

• blood safety

• transplantation

• immunosuppression

• HIV infection

35. Monitoring Chronic HBV

Monitoring should be individualized according to:

• HBeAg status

• HBV DNA

• ALT

• fibrosis

• age

• family history

• treatment status

• cirrhosis

• HCC risk

• coinfections

A single measurement is insufficient in many patients.

Why?

Because:

ALT fluctuates

and

HBV DNA fluctuates

Therefore, longitudinal assessment is crucial.

36. Practical Clinical Assessment

A patient newly identified as HBsAg positive should generally undergo:

Confirm chronicity

↓

Assess HBeAg/anti-HBe

↓

Quantify HBV DNA

↓

Measure ALT/AST

↓

Assess fibrosis/cirrhosis

↓

Screen for HDV and other relevant coinfections

↓

Assess HCC risk

↓

Determine need for antiviral treatment

↓

Establish monitoring plan

37. Liver Fibrosis Assessment

Non-invasive assessment is increasingly important.

Methods include:

Transient elastography

Measures liver stiffness.

Serum-based scores

Examples:

• APRI

• FIB-4

Imaging

• ultrasonography

• other liver imaging when clinically indicated

Liver biopsy

May be considered when:

• diagnosis is uncertain

• non-invasive tests are discordant

• histological grading/staging will alter management

38. HCC Surveillance

Patients at sufficiently high risk require regular HCC surveillance.

The exact surveillance strategy depends on:

• cirrhosis

• age

• sex

• family history

• ethnicity/epidemiology

• HBV-related risk

• other risk factors

Ultrasound-based surveillance, with or without AFP depending on guideline and clinical setting, is commonly used.

39. Treatment Implications

Treatment is covered separately in 202. HBV Treatment, but the principles are important here.

The major goal is to:

• suppress HBV replication

• reduce hepatic inflammation

• prevent fibrosis progression

• prevent cirrhosis

• reduce HCC risk

• reduce liver-related mortality

• achieve HBsAg loss whenever possible

Common high-barrier nucleos(t)ide analogues include:

• tenofovir

• entecavir

Current treatment eligibility is broader and more individualized than the traditional "ALT >2× ULN + HBV DNA threshold" approach.

40. Why Treatment Decisions Cannot Depend on HBV DNA Alone

Consider two patients:

Patient A

HBV DNA:

100,000,000 IU/mL

ALT:

Normal

Fibrosis:

Minimal

Patient B

HBV DNA:

5,000 IU/mL

ALT:

Elevated

Fibrosis:

Advanced

Patient B may have substantially greater immediate liver-related risk.

Therefore:

41. Current Guideline Direction

Modern guidelines emphasize:

• longitudinal assessment

• non-invasive fibrosis assessment

• broader treatment eligibility

• recognition of indeterminate/grey-zone patients

• HCC risk assessment

• HDV testing

• prevention of mother-to-child transmission

• long-term monitoring

The WHO 2024 guideline substantially expanded and simplified treatment eligibility, diagnostics and monitoring approaches.

The 2025 AASLD/IDSA guidance also explicitly recognizes immune-active, inactive and indeterminate states, emphasizing individualized treatment decisions rather than rigid phase labels.

42. Chronic HBV — Complete Natural History Flowchart

HBV infection
      ↓
Persistence ≥6 months
      ↓
CHRONIC HBV INFECTION
      ↓
┌─────────────────────────────────────┐
│                                     │
↓                                     ↓
HBeAg-positive                    HBeAg-negative
│                                     │
↓                                     ↓
Chronic infection                 Chronic infection
│                                     │
↓                                     ↓
Chronic hepatitis                 Chronic infection
│                                     │
↓                                     ↓
HBeAg seroconversion               Reactivation possible
│                                     │
↓                                     ↓
HBeAg-negative chronic infection  HBeAg-negative chronic hepatitis
│                                     │
└──────────────────┬──────────────────┘
                   ↓
          Persistent inflammation
                   ↓
                Fibrosis
                   ↓
                Cirrhosis
              ↙          ↘
   Decompensation         HCC

43. The Most Important Conceptual Model

Think of chronic HBV using four variables:

1. Virus

HBV DNA

How much virus is replicating?

2. Antigenic state

HBeAg / HBsAg

What is the viral phenotype?

3. Host response

ALT

Is the liver being injured?

4. Liver damage

Fibrosis/cirrhosis

How much structural damage has accumulated?

Therefore:

44. High-Yield Exam Pearls

Pearl 1

HBsAg ≥6 months → chronic HBV infection.

Pearl 2

HBeAg negative does NOT mean HBV DNA negative.

Pearl 3

Precore/basal core promoter variants can produce HBeAg-negative active hepatitis.

Pearl 4

HBeAg seroconversion ≠ cure.

Pearl 5

HBsAg loss = functional cure / best serological endpoint.

Pearl 6

cccDNA can persist despite serum HBV DNA suppression.

Pearl 7

HBV-associated HCC can occur without cirrhosis.

Pearl 8

Normal ALT does not automatically exclude significant liver disease.

Pearl 9

HBV DNA and ALT may fluctuate substantially.

Pearl 10

"Inactive carrier" is older terminology; HBeAg-negative chronic infection is preferred.

Pearl 11

HDV coinfection can markedly accelerate liver disease.

Pearl 12

Immunosuppression can cause HBV reactivation.

Pearl 13

Anti-HBc generally persists after resolution and throughout chronic infection.

Pearl 14

Chronic HBV is a dynamic disease, not a fixed four-stage sequence.

Pearl 15

Treatment decisions require assessment of viral replication + ALT + fibrosis + HCC risk + patient-specific factors.

45. One-Minute Revision

Chronic HBV = HBsAg ≥6 months

↓

cccDNA persists in hepatocyte nucleus

↓

Disease is largely immune-mediated

↓

Four major clinical states:

1. HBeAg-positive chronic infection

• HBeAg+

• very high HBV DNA

• normal ALT

• little inflammation

2. HBeAg-positive chronic hepatitis

• HBeAg+

• high HBV DNA

• ALT ↑

• active inflammation

3. HBeAg-negative chronic infection

• HBeAg−

• usually anti-HBe+

• HBV DNA usually <2,000 IU/mL

• ALT normal

4. HBeAg-negative chronic hepatitis

• HBeAg−

• HBV DNA elevated/fluctuating

• ALT elevated/fluctuating

• often associated with precore/core promoter variants

↓

Repeated inflammation

↓

Fibrosis

↓

Cirrhosis

↓

Decompensation ± HCC

46. Final Take-Home Message

Chronic hepatitis B is best understood as a dynamic interaction between HBV replication, viral antigen expression, host immune control and accumulated liver injury.

The most important clinical mistake is to equate:

HBV DNA level = disease severity

That is incorrect.

A proper assessment requires:

HBsAg duration + HBeAg status + HBV DNA + ALT + fibrosis + HCC risk + coinfections + patient-specific factors.

The ultimate goal of long-term management is to prevent:

chronic inflammation → fibrosis → cirrhosis → hepatic failure/HCC

while achieving sustained viral suppression and, ideally, HBsAg loss (functional cure).

47. Standard References

1. Knipe DM, Howley PM, editors. Fields Virology: DNA Viruses. Wolters Kluwer.

2. Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases.

3. Carroll KC, Pfaller MA, Landry ML, et al. Manual of Clinical Microbiology.

4. Murray PR, Rosenthal KS, Pfaller MA. Medical Microbiology.

5. Brooks GF, et al. Jawetz, Melnick & Adelberg's Medical Microbiology.

6. Ryan KJ, Ray CG. Sherris Medical Microbiology.

7. World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. WHO; 2024.

8. World Health Organization. Consolidated guidance on hepatitis B and C prevention, testing, treatment, service delivery and monitoring. WHO; 2026.

9. AASLD/IDSA. Practice Guideline on Treatment of Chronic Hepatitis B. Hepatology; 2025.

10. Ganem D, Prince AM. Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med.

11. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol.

12. Bertoletti A, Ferrari C. Adaptive immunity in HBV and HCV infections. Nat Rev Immunol.

13. Maini MK, Burton AR. Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. Nat Rev Gastroenterol Hepatol.

14. Locarnini S, Hatzakis A, Chen DS, Lok A. Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs. J Hepatol.

15. European Association for the Study of the Liver. Clinical Practice Guidelines on the management of hepatitis B.